IL205313A0 - Pharmaceutical formulation of clavulanic acid - Google Patents

Pharmaceutical formulation of clavulanic acid

Info

Publication number
IL205313A0
IL205313A0 IL205313A IL20531310A IL205313A0 IL 205313 A0 IL205313 A0 IL 205313A0 IL 205313 A IL205313 A IL 205313A IL 20531310 A IL20531310 A IL 20531310A IL 205313 A0 IL205313 A0 IL 205313A0
Authority
IL
Israel
Prior art keywords
pharmaceutical formulation
clavulanic acid
clavulanic
acid
formulation
Prior art date
Application number
IL205313A
Other languages
English (en)
Original Assignee
Rexahn Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Pharmaceuticals Inc filed Critical Rexahn Pharmaceuticals Inc
Publication of IL205313A0 publication Critical patent/IL205313A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL205313A 2007-10-26 2010-04-25 Pharmaceutical formulation of clavulanic acid IL205313A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99607907P 2007-10-26 2007-10-26
PCT/US2008/012126 WO2009055038A1 (en) 2007-10-26 2008-10-24 Pharmaceutical formulation of clavulanic acid

Publications (1)

Publication Number Publication Date
IL205313A0 true IL205313A0 (en) 2010-12-30

Family

ID=40579869

Family Applications (1)

Application Number Title Priority Date Filing Date
IL205313A IL205313A0 (en) 2007-10-26 2010-04-25 Pharmaceutical formulation of clavulanic acid

Country Status (11)

Country Link
US (1) US20090270358A1 (enExample)
EP (1) EP2214680A4 (enExample)
JP (1) JP2011500811A (enExample)
KR (1) KR20100101574A (enExample)
CN (1) CN101918004A (enExample)
AU (1) AU2008317315A1 (enExample)
BR (1) BRPI0818702A2 (enExample)
CA (1) CA2703224A1 (enExample)
IL (1) IL205313A0 (enExample)
MX (1) MX2010004556A (enExample)
WO (1) WO2009055038A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255099A1 (en) * 2007-10-26 2010-10-07 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
KR101628095B1 (ko) 2010-10-18 2016-06-08 현대자동차 주식회사 저압 ｅｇｒ시스템 제어장치 및 방법
CN102058584B (zh) * 2010-12-30 2012-01-25 石药集团河北中润制药有限公司 克拉维酸钾/微晶纤维素组合物的制备方法
US9751957B2 (en) 2012-02-15 2017-09-05 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
KR102112119B1 (ko) 2012-10-22 2020-05-19 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
EP2919903B1 (en) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions containing a biologically active material and a non-ordered inorganic oxide
WO2015153984A2 (en) 2014-04-04 2015-10-08 Pharmaquest International Center, LLC Disintegrating monolithic modified release tablets containing quadri-layer extended release granules

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
NZ189022A (en) * 1977-12-08 1981-11-19 Beecham Group Ltd Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9405856D0 (en) * 1994-03-24 1994-05-11 Smithkline Beecham Plc Pharmaceutical formulation
GB9518917D0 (en) * 1995-09-15 1995-11-15 Smithkline Beecham Plc Compounds
IE990159A1 (en) * 1999-02-26 2000-09-20 Fuisz Internat Ltd Storage Stable Amoxycillin and Clavulanate Suspension Composition.
BR0013366A (pt) 1999-08-16 2002-07-23 Revaax Pharmaceuticals Llc Métodos para tratar um distúrbio comportamental, um paciente humano, doença de próstata, distúrbios de ansiedade e cognitivos em um paciente humano afligido com uma condição ou disposto ao desenvolvimento de uma condição distinguida pelo menos em parte pela concentração de glutamato extracelular anormal no cérebro ou em outro tecido nervoso, distúrbio comportamental nas espécies humana, canina, felina e equina e um paciente afligido com ou disposto a desenvolver uma doença compreendendo concentrações de glutamato anormalmente elevadas em tecido neuronal ou nìveis de naaladase elevados em tecido prostático e com esclerose múltipla e para realçar a função cognitiva, formulação farmacêutica e usos de um inibidor da atividade de peptidase de uma dipeptidase ácida ligada em alfa n-acetilada e de um composto de beta-lactama
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
US7166626B2 (en) 2001-06-18 2007-01-23 Revaax Pharmaceuticals, Llc Therapeutic treatment for sexual dysfunction
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
PE20060489A1 (es) * 2004-08-13 2006-06-19 Schering Plough Ltd Formulacion farmaceutica que comprende un antibiotico, un triazol y un corticosteroide
DE102006007830A1 (de) * 2006-02-17 2007-08-30 Grünenthal GmbH Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure
CA2644911A1 (en) * 2006-03-24 2007-10-04 Panacea Biotec Ltd. Antibiotic compositions of modified release and process of production thereof
US20100255099A1 (en) * 2007-10-26 2010-10-07 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
JP2011500811A (ja) 2011-01-06
CN101918004A (zh) 2010-12-15
EP2214680A1 (en) 2010-08-11
WO2009055038A1 (en) 2009-04-30
AU2008317315A1 (en) 2009-04-30
MX2010004556A (es) 2010-07-01
EP2214680A4 (en) 2010-12-29
BRPI0818702A2 (pt) 2015-04-22
CA2703224A1 (en) 2009-04-30
KR20100101574A (ko) 2010-09-17
US20090270358A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
HUS1800043I1 (hu) 514 számú gyógyszerkészítmény
ZA200900345B (en) Preparation of pharmaceutical formulations
GB2450753B (en) New Pharmaceutical formulation
IL211099A0 (en) Formulation for oral administration of proteins
PT2413913T (pt) Formulações farmacêuticas que compreendem derivados de nitrocatecol e métodos para os preparar
ZA201200719B (en) Pharmaceutical formulation
SI2173345T1 (sl) Oralna formulacija metadoksina
IL205313A0 (en) Pharmaceutical formulation of clavulanic acid
IL210835A0 (en) Processes for the preparation of 4-oxo-octahydro-indole-1-carboxylic acid methyl ester and derivatives thereof
HUE038257T2 (hu) Tetraciklin vegyület orális tabletta formulációja
IL208788A (en) Pharmacy-based formulation
IL213711A (en) Nano-phenofibrate preparation
PL385972A1 (pl) Kompozycja farmaceutyczna do leczenia chorób przyzębia
EP2157089A4 (en) THERAPEUTIC USES OF IMIDAZOL-5-CARBOXYLIC ACID DERIVATIVES
ZA201101053B (en) Pharmaceutical compositions of samatotrophic hormones
ZA201004864B (en) Amino acid derivatives used as pharmaceutical substances
HU0900482D0 (en) Pharmaceutical formulation for oral administration
PT2519261E (pt) Composição farmacêutica líquida oral de nifedipina
AU2008903115A0 (en) Pharmaceutical Formulation
GB0805292D0 (en) Pharmaceutical formulation
GB0906003D0 (en) Oral drug formulation
HK1156841A (en) Pharmaceutical formulation of ketorolac for intranasal administration
GB0705030D0 (en) Pharmaceutical formulation
HK1168781A (en) Nitrile derivatives and their pharmaceutical use and compositions
GB0810217D0 (en) Pharmaceutical formulations